Tempest Therapeutics Files 8-K on Security Holder Rights
Ticker: TPST · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: rights-modification, corporate-action, filing
Related Tickers: TPST
TL;DR
Tempest Therapeutics (TPST) filed an 8-K on 4/4/25 regarding changes to security holder rights. Stay tuned for details.
AI Summary
On April 4, 2025, Tempest Therapeutics, Inc. filed an 8-K to report material modifications to the rights of security holders and financial statements. The filing indicates a change in the company's structure or rights associated with its securities, though specific details of the modifications are not elaborated in the provided text.
Why It Matters
This filing signals potential changes affecting the rights and ownership structure for Tempest Therapeutics' security holders, requiring their attention.
Risk Assessment
Risk Level: medium — Filings concerning modifications to security holder rights can indicate significant corporate events that may impact stock value and investor positions.
Key Numbers
- 001-35890 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-1472564 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- April 4, 2025 (date) — Date of earliest event reported
- 2000 Sierra Point Parkway, Suite 400 (address) — Company Business Address
- Millendo Therapeutics, Inc. (company) — Former Company Name
- OvaScience, Inc. (company) — Former Company Name
FAQ
What specific modifications were made to the rights of security holders?
The provided text of the 8-K filing does not specify the exact nature of the material modifications to the rights of security holders.
What is the significance of filing under Item 3.03 and Item 9.01?
Item 3.03 pertains to Material Modifications to Rights of Security Holders, and Item 9.01 covers Financial Statements and Exhibits, indicating changes in rights and the inclusion of financial documents.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 4, 2025.
What is Tempest Therapeutics, Inc.'s former company name?
Tempest Therapeutics, Inc. was formerly known as Millendo Therapeutics, Inc. and prior to that, OvaScience, Inc.
Where is Tempest Therapeutics, Inc. located?
Tempest Therapeutics, Inc. is located at 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding Tempest Therapeutics, Inc. (TPST).